References
- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
- Abe S, Yoshizawa M, Nakanishi N, et al. Electrocardiographic abnormalities in patients receiving hemodialysis. Am Heart J. 1996;131:1137–1144
- Erem C, Kulan K, Tuncer C, Bostan M, Mocan Z, Komsuoglu B. Cardiac arrhythmias in patients on maintenance hemodialysis. Acta Cardiol. 1997;52:25–36
- Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J. 1990;63:342–344
- Bazett H. An analysis of time relations of the electrocardiogram. Heart. 1920;7:353–370
- Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet. 1994;343:327–329
- Beaubien ER, Pylypchuk GB, Akhtar J, Biem HJ. Value of corrected QT interval dispersion in identifying patients initiating dialysis at increased risk of total and cardiovascular mortality. Am J Kidney Dis. 2002;39:834–842
- Surawicz B. Will QT dispersion play a role in clinical decision‐making? [editorial; comment]. J Cardiovasc Electrophysiol. 1996;7:777–784
- Statters DJ, Malik M, Ward DE, Camm AJ. QT dispersion: problems of methodology and clinical significance. J Cardiovasc Electrophysiol. 1994;5:672–685
- Wu VC, Lin LY, Wu KD. QT interval dispersion in dialysis patients. Nephrology (Carlton). 2005;10(2):109–112
- Averbukh Z, Rosenberg R, Galperin E, et al. Cell-associated magnesium and QT dispersion in hemodialysis patients. Am J Kidney Dis. 2003;41:196–202
- Howse M, Sastry S, Bell GM. Changes in the corrected QT interval and corrected QT dispersion during hemodialysis. Postgrad Med J. 2002;78:273–275
- Siah CW, Trinder D, Olynyk JK. Iron overload. Clin Chim Acta. 2005;358:24–36
- Fitchett DH, Coltart DJ, Littler WA, et al. Cardiac involvement in secondary hemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res. 1980;14:719–724
- Kuryshev YA, Brittenham GM, Fujioka H, et al. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease. Circulation. 1999;100:675–683
- Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003;289(16):2120--2127
- Wood JC, Enriquez C, Ghugre N, et al. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci. 2005;1054:386–395
- Horackova M, Ponka P, Byczko Z. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H(2)O(2) injury in adult cardiomyocytes. Cardiovasc Res. 2000;47(3):529–536
- Neckář J, Boudíková A, Mandíková P, et al. Protective effects of dexrazoxane against acute ischemia/reperfusion injury of rat hearts. Can J Physiol Pharmacol. 2012;90(9):1303–1310
- Kyriacou K, Michaelides Y, Senkus R, et al. Ultrastructural pathology of the heart in patients with β-thalassanemia major. Ultrastruct Pathol. 2000;24(2):75–81
- Murphy CJ, Oudit GY. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail. 2010;16(11):888–900
- Arvapalli RK, Paturi S, Laurino JP, et al. Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver. Cardiovasc Toxicol. 2010;10:108–116
- Wang Y, Wu M, Al-Rousan R, et al. Iron-induced cardiac damage: role of apoptosis and deferasirox intervention. J Pharmacol Exp Ther. 2011;336(1):56–63
- Schwartz KA, Li Z, Schwartz DE, et al. Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. J Appl Physiol. 2002;93(2):746–751
- Wu VC, Huang JW, Wu MS, et al. The effect of iron stores on corrected QT dispersion in patients undergoing peritoneal dialysis. Am J Kidney Dis. 2004;44:720–728